search

Active clinical trials for "Lymphoproliferative Disorders"

Results 161-170 of 217

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who...

LeukemiaLymphoma

RATIONALE: Donor lymphocytes that have been exposed to Epstein-Barr virus may be able to help the body kill cancers associated with this virus. PURPOSE: Phase I trial to study the effectiveness of Epstein-Barr virus-specific T cells derived from matched donors in organ transplant patients with lymphoproliferative diseases associated with Epstein-Barr virus.

Withdrawn17 enrollment criteria

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

Brain and Central Nervous System TumorsLymphoma2 more

RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with GM-CSF may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy together with GM-CSF works in treating patients with CNS lymphoma.

Withdrawn29 enrollment criteria

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic...

Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome53 more

This study will determine the safety and applicability of experimental forms of umbilical cord blood (UCB) transplantation for patients with high risk hematologic malignancies who might benefit from a hematopoietic stem cell transplant (HSCT) but who do not have a standard donor option (no available HLA-matched related donor (MRD), HLA-matched unrelated donor (MUD)), or single UCB unit with adequate cell number and HLA-match).

Withdrawn38 enrollment criteria

Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders

LeukemiaLymphoproliferative Disorders

The goal of this clinical research study is to learn the highest tolerable dose of phenethyl isothiocyanate (PEITC) that can be given to patients who have a lymphoproliferative disorder that has been treated with fludarabine. The safety of PEITC will also be studied.

Withdrawn10 enrollment criteria

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr...

Gastric CancerHead and Neck Cancer2 more

RATIONALE: The Epstein-Barr virus can cause cancer and lymphoproliferative disorders. Valganciclovir is an antiviral drug that acts against the Epstein-Barr virus. Phenylbutyrate may make cells infected with Epstein-Barr virus more sensitive to valganciclovir. Giving phenylbutyrate together with valganciclovir may block the growth of Epstein-Barr virus-infected cells and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving phenylbutyrate together with valganciclovir works in treating patients with relapsed or refractory Epstein-Barr virus-positive cancer.

Withdrawn40 enrollment criteria

Familial B-cell Lymphoproliferative Disorders

Lymphoproliferative DisordersPremalignant2 more

This study investigates families with at least two cases of B-cell lymphoproliferative disorders (LPD), and evaluates the prevalence of LPD in families, the relationship between medical history, genetic factors, and the risk of familial LPD, and various clinical outcomes for these families in a multiethnic population of Jews and Arabs in Israel.

Not yet recruiting6 enrollment criteria

Clonal Hematopoiesis of Immunological Significance

Immune System DiseasesAutoimmune Diseases14 more

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Not yet recruiting5 enrollment criteria

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis...

Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin Lymphoma1 more

This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.

Not yet recruiting4 enrollment criteria

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With...

AnemiaLeukemia6 more

RATIONALE: Darbepoetin alfa may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues. It is not yet known whether giving darbepoetin alfa (DA) together with intravenous iron or oral iron is more effective than giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy. PURPOSE: This randomized phase III trial is studying giving darbepoetin alfa together with iron to see how well it works compared with giving darbepoetin alfa together with a placebo in treating anemia caused by chemotherapy in patients with cancer.

Completed35 enrollment criteria

American Ginseng in Treating Patients With Fatigue Caused by Cancer

Chronic Myeloproliferative DisordersFatigue9 more

RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue. PURPOSE: This randomized phase III trial is studying American ginseng to see how well it works in treating patients with fatigue caused by cancer.

Completed43 enrollment criteria
1...161718...22

Need Help? Contact our team!


We'll reach out to this number within 24 hrs